Physician profile
Maggie Chen
NPI 1487316030
$6,449.73
in general payments reported to CMS, 2019-2025
35 companies · $2,590 in 2025
The $2,590 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,129 · 2024: $2,731 · 2025: $2,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,449.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,325.33 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $892.58 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $405.89 | 2024-2025 | Jynarque, Rexulti |
| Lilly USA, LLC | $371.31 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $330.44 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $304.34 | 2023-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $275.64 | 2023-2025 | Freestyle Libre 3, Assurity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $256.65 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.61 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $228.57 | 2024-2025 | |
| Corcept Therapeutics | $187.98 | 2023-2025 | Korlym |
| Glaxosmithkline, LLC. | $171.47 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $135.28 | 2024-2025 | Verquvo |
| Abiomed | $119.73 | 2025 | |
| Sumitomo Pharma America, INC. | $111.52 | 2025 | Gemtesa |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $103.18 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $101.86 | 2024-2025 | Veozah |
| Grifols USA, LLC | $100.84 | 2024-2025 | Prolastin-C Liquid |
| Pfizer INC. | $97.07 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.60 | 2024-2025 | Glassia |
| Xeris Pharmaceuticals, INC. | $80.65 | 2024-2025 | Recorlev |
| Janssen Pharmaceuticals, INC | $77.30 | 2024 | Spravato, Xarelto |
| Exact Sciences Corporation | $73.88 | 2023-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $58.28 | 2024-2025 | Fanapt, Hetlioz |
| Globus Medical, INC. | $50.66 | 2025 | Senza |
| Inspire Medical Systems, INC. | $44.76 | 2024-2025 | Inspire |
| Axsome Therapeutics, INC. | $42.87 | 2025 | Auvelity |
| Currax Pharmaceuticals LLC | $34.44 | 2025 | Contrave |
| Philips North America LLC | $26.50 | 2024 | (Ck7) Extended Holter |
| Phathom Pharmaceuticals, INC. | $26.10 | 2024 | Voquezna |
| Mylan Specialty L.P. | $21.05 | 2024 | Yupelri |
| Evoke Pharma, INC. | $19.95 | 2025 | |
| Scilex Pharmaceuticals INC. | $16.77 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.19 | 2024 | Xifaxan |
| Insulet Corporation | $15.44 | 2025 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maggie Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.